About this trial
Dexmedetomidine can attenuate the activity of the sympathetic nervous system under stress response and improve ischemia-reperfusion injury. The investigators hypothesized that the prolonged sedation of dexmedetomidine after successful reperfusion of endovascular thrombectomy may improve the clinical outcome of acute ischemic stroke patients.
Eligibility criteria
Qualifiers
2≤NIHSS≤25
mRS score before stroke was less than 3
Acute ischemic stroke (including anterior circulation)
mTICI rate 2b or 3
Disqualifiers
Intracerebral hemorrhage occurred in the responsible vessel area in the past 6 weeks
Patients who had received stent treatment at the responsible vessel in the past
Neurological function was restored at or before angiography
Patients who are allergic to heparin, aspirin, clopidogrel, rapamycin, lactic acid polymer, poly (n-butyl methacrylate), stainless steel, anesthetics and contrast agents or have contraindications
Trial design
Treatments tested in this trial
- Dexmedetomidine prolonged sedation
- 0.9% saline